Condition: ST Segment Elevation Myocardial Infarction (STEMI) · Cardiogenic Shock Post Myocardial Infarction · Sponsor: Tel-Aviv Sourasky Medical Center
This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit. When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups. During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations. The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.
This description comes directly from the study's public registry record.
Shir Frydman, MD · 0544267898 · shirfrydman@gmail.com
Yishay Szekely, MD · yishay.szekely@gmail.com
Always discuss trial participation with your own doctor first.
| Tel Aviv Sourasky Medical center | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06967194